SEBA:GETTEXSkandinaviska Enskilda Banken AB Class A Analysis
Data as of 2026-06-19 - not real-time
€17.82
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Skandinaviska Enskilda Banken is trading at €17.82, comfortably above its 20‑day SMA of 17.11 and 50‑day SMA of 16.82, yet just shy of the recent resistance around €17.85. The RSI sits at 65, suggesting the stock is approaching overbought territory but still has room before a classic reversal. A bullish MACD (line above signal) adds momentum support, while increasing volume signals renewed investor interest. The valuation metrics are compelling: a PE of 12.6 versus the industry average of 16.9 and a price‑to‑book of only 0.16 point to significant upside potential. Dividend sustainability looks solid with a 4.38% yield and a payout ratio near 55%, indicating the bank can comfortably maintain its cash returns. Low beta (0.59) and a 30‑day volatility of about 22% suggest moderate price swings, aligning with the “Extreme Greed” market sentiment reflected in the fear‑greed index. Overall, the stock balances attractive valuation, strong dividend appeal, and modest risk, making it a noteworthy candidate for investors seeking value with a dividend edge.
The regional banking sector faces moderate regulatory scrutiny and interest‑rate sensitivity, but SEB’s diversified geographic footprint—from Scandinavia to broader Europe and select Asian markets—mitigates concentration risk. While the price hovers near resistance, the technical backdrop remains supportive, and the fundamental profile (solid ROE of 13.6% and healthy cash generation) underpins a positive outlook. Investors should monitor the near‑term price action for a potential pull‑back to the support level around €16.6, but the longer‑term narrative remains bullish.
The regional banking sector faces moderate regulatory scrutiny and interest‑rate sensitivity, but SEB’s diversified geographic footprint—from Scandinavia to broader Europe and select Asian markets—mitigates concentration risk. While the price hovers near resistance, the technical backdrop remains supportive, and the fundamental profile (solid ROE of 13.6% and healthy cash generation) underpins a positive outlook. Investors should monitor the near‑term price action for a potential pull‑back to the support level around €16.6, but the longer‑term narrative remains bullish.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with elevated RSI
- Bullish MACD supporting upward bias
- Increasing volume indicating short‑term interest
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued valuation relative to peers
- Strong dividend yield and sustainable payout
- Low beta and moderate volatility
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust fundamentals (ROE, dividend sustainability)
- Diversified geographic exposure reducing concentration risk
- Attractive price‑to‑book and PE multiples
Key Metrics & Analysis
Financial Health
Revenue Growth-6.80%
Profit Margin41.48%
P/E Ratio12.6
ROE13.63%
ROA0.75%
P/B Ratio0.2
Industry P/E16.9
Technical Analysis
TrendNeutral
RSI65.4
Support€16.60
Resistance€17.84
MA 20€17.11
MA 50€16.82
MA 200€17.09
MACDBullish
VolumeIncreasing
Fear & Greed Index92.14
Valuation
GradeUndervalued
TypeBlend
Dividend Yield4.38%
Risk Assessment
Beta0.59
Volatility22.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.